Promising Efficacy and Safety of Arcus Biosciences’ Combination Therapy Reinforces Buy Rating

Arcus Biosciences (RCUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $24.00 price target.

Emily Bodnar’s rating is based on promising early data from Arcus Biosciences’ combination therapy of casdatifan (cas) and cabozantinib (cabo) for treating clear cell renal cell carcinoma. The data presented at ASCO showed encouraging efficacy with a confirmed objective response rate (ORR) of 46%, including complete and partial responses, without increased safety concerns. The combination therapy demonstrated synergy, achieving better response rates than either agent alone, which suggests potential for further benefits with continued follow-up.
Furthermore, the safety profile of the combination was consistent with expectations, with no patients discontinuing both therapies due to adverse events. The high disease control rate (DCR) of 96% and the fact that all responders remain on therapy indicate a favorable outcome. These positive results provide a strong proof of concept for the upcoming Phase 3 trial, reinforcing the Buy rating for Arcus Biosciences’ stock.

Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Agenus, and Femasys. According to TipRanks, Bodnar has an average return of -5.2% and a 29.79% success rate on recommended stocks.